APO Research
Talk to an analyst

APO RESEARCH · REPORT

Innovative Drug CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Innovative Drug CDMO Market Outlook and Growth Opportunities 2026

4 January 2026193 pages

Choose your research edition.

Industry ResearchInnovative Drug CDMO Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Innovative Drug CDMO Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Innovative Drug CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Innovative Drug CDMO Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Innovative Drug CDMO Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Innovative Drug CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Innovative Drug CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Innovative Drug CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Innovative Drug CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Innovative Drug CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Innovative Drug CDMO market include Skyepharma, Asymchem, Recipharm, Bend Bioscience, Pierre Fabre, Axplora, Quotient Sciences, Lonza and Ardena, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Innovative Drug CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Innovative Drug CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Innovative Drug CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Innovative Drug CDMO market.

Innovative Drug CDMO Segment by Company

Skyepharma

Asymchem

Recipharm

Bend Bioscience

Pierre Fabre

Axplora

Quotient Sciences

Lonza

Ardena

Hovione

Resilience

AGC Biologics

Patheon Pharma Services

Samsung Biologics

Catalent

Innovative Drug CDMO Segment by Type

Small Molecule CDMO

Macromolecule CDMO

Cell Gene Therapy (CGT) CDMO

Innovative Drug CDMO Segment by Application

Oncology and Cancer Drugs

Autoimmune Disease Drugs

Rare Disease Drugs

Gene Therapy Drugs

Metabolic Disease Drugs

Others

Innovative Drug CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Innovative Drug CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Innovative Drug CDMO key companies, revenue, market share, and recent developments.

3. To split the Innovative Drug CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Innovative Drug CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Innovative Drug CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Innovative Drug CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Innovative Drug CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Innovative Drug CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Innovative Drug CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Innovative Drug CDMO industry.

Chapter 3: Detailed analysis of Innovative Drug CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Innovative Drug CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Innovative Drug CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Innovative Drug CDMO Industry Trends Table 2. Innovative Drug CDMO Industry Drivers Table 3. Innovative Drug CDMO Industry Opportunities and Challenges Table 4. Innovative Drug CDMO Industry Restraints Table 5. Global Innovative Drug CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Innovative Drug CDMO Revenue Share by Company (2021-2026) Table 7. Global Innovative Drug CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Innovative Drug CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Innovative Drug CDMO Company, Product Type & Application Table 10. Global Innovative Drug CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Innovative Drug CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Small Molecule CDMO Table 15. Significant Companies of Macromolecule CDMO Table 16. Significant Companies of Cell Gene Therapy (CGT) CDMO Table 17. Global Innovative Drug CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Innovative Drug CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Innovative Drug CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Innovative Drug CDMO Sales Value Share by Type (2021-2026) Table 21. Global Innovative Drug CDMO Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Oncology and Cancer Drugs Table 23. Significant Companies of Autoimmune Disease Drugs Table 24. Significant Companies of Rare Disease Drugs Table 25. Significant Companies of Gene Therapy Drugs Table 26. Significant Companies of Metabolic Disease Drugs Table 27. Significant Companies of Others Table 28. Global Innovative Drug CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Innovative Drug CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Innovative Drug CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Innovative Drug CDMO Sales Value Share by Application (2021-2026) Table 32. Global Innovative Drug CDMO Sales Value Share by Application (2027-2032) Table 33. Global Innovative Drug CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Innovative Drug CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Innovative Drug CDMO Sales Value Share by Region (2021-2026) Table 36. Global Innovative Drug CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Innovative Drug CDMO Sales Value Share by Region (2027-2032) Table 38. Global Innovative Drug CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Innovative Drug CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Innovative Drug CDMO Sales Value Market Share by Country (2021-2026) Table 41. Global Innovative Drug CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Innovative Drug CDMO Sales Value Market Share by Country (2027-2032) Table 43. Skyepharma Company Information Table 44. Skyepharma Business Overview Table 45. Skyepharma Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Skyepharma Innovative Drug CDMO Product Portfolio Table 47. Skyepharma Recent Development Table 48. Asymchem Company Information Table 49. Asymchem Business Overview Table 50. Asymchem Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Asymchem Innovative Drug CDMO Product Portfolio Table 52. Asymchem Recent Development Table 53. Recipharm Company Information Table 54. Recipharm Business Overview Table 55. Recipharm Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Recipharm Innovative Drug CDMO Product Portfolio Table 57. Recipharm Recent Development Table 58. Bend Bioscience Company Information Table 59. Bend Bioscience Business Overview Table 60. Bend Bioscience Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Bend Bioscience Innovative Drug CDMO Product Portfolio Table 62. Bend Bioscience Recent Development Table 63. Pierre Fabre Company Information Table 64. Pierre Fabre Business Overview Table 65. Pierre Fabre Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pierre Fabre Innovative Drug CDMO Product Portfolio Table 67. Pierre Fabre Recent Development Table 68. Axplora Company Information Table 69. Axplora Business Overview Table 70. Axplora Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Axplora Innovative Drug CDMO Product Portfolio Table 72. Axplora Recent Development Table 73. Quotient Sciences Company Information Table 74. Quotient Sciences Business Overview Table 75. Quotient Sciences Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Quotient Sciences Innovative Drug CDMO Product Portfolio Table 77. Quotient Sciences Recent Development Table 78. Lonza Company Information Table 79. Lonza Business Overview Table 80. Lonza Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Lonza Innovative Drug CDMO Product Portfolio Table 82. Lonza Recent Development Table 83. Ardena Company Information Table 84. Ardena Business Overview Table 85. Ardena Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Ardena Innovative Drug CDMO Product Portfolio Table 87. Ardena Recent Development Table 88. Hovione Company Information Table 89. Hovione Business Overview Table 90. Hovione Innovative Drug CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Hovione Innovative Drug CDMO Product Portfolio Table 92. Hovione Recent Development Table 93. Resilience Company Information Table 94. Resilience Business Overview Table 95. Resilience Innovative Drug CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Resilience Innovative Drug CDMO Product Portfolio Table 97. Resilience Recent Development Table 98. AGC Biologics Company Information Table 99. AGC Biologics Business Overview Table 100. AGC Biologics Innovative Drug CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. AGC Biologics Innovative Drug CDMO Product Portfolio Table 102. AGC Biologics Recent Development Table 103. Patheon Pharma Services Company Information Table 104. Patheon Pharma Services Business Overview Table 105. Patheon Pharma Services Innovative Drug CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Patheon Pharma Services Innovative Drug CDMO Product Portfolio Table 107. Patheon Pharma Services Recent Development Table 108. Samsung Biologics Company Information Table 109. Samsung Biologics Business Overview Table 110. Samsung Biologics Innovative Drug CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Samsung Biologics Innovative Drug CDMO Product Portfolio Table 112. Samsung Biologics Recent Development Table 113. Catalent Company Information Table 114. Catalent Business Overview Table 115. Catalent Innovative Drug CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Catalent Innovative Drug CDMO Product Portfolio Table 117. Catalent Recent Development Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Innovative Drug CDMO Product Image Figure 2. Global Innovative Drug CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Innovative Drug CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Innovative Drug CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Small Molecule CDMO Image Figure 8. Macromolecule CDMO Image Figure 9. Cell Gene Therapy (CGT) CDMO Image Figure 10. Global Innovative Drug CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Innovative Drug CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Innovative Drug CDMO Sales Value Share by Type (2021-2032) Figure 13. Oncology and Cancer Drugs Image Figure 14. Autoimmune Disease Drugs Image Figure 15. Rare Disease Drugs Image Figure 16. Gene Therapy Drugs Image Figure 17. Metabolic Disease Drugs Image Figure 18. Others Image Figure 19. Global Innovative Drug CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Innovative Drug CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Innovative Drug CDMO Sales Value Share by Application (2021-2032) Figure 22. Global Innovative Drug CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Innovative Drug CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Innovative Drug CDMO Sales Value (2021-2032) & (US$ Million) Figure 25. North America Innovative Drug CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Innovative Drug CDMO Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Innovative Drug CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Innovative Drug CDMO Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Innovative Drug CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Innovative Drug CDMO Sales Value (2021-2032) & (US$ Million) Figure 31. South America Innovative Drug CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Innovative Drug CDMO Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Innovative Drug CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Innovative Drug CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule CDMO
  • Macromolecule CDMO
  • Cell Gene Therapy (CGT) CDMO
Applications
  • Oncology and Cancer Drugs
  • Autoimmune Disease Drugs
  • Rare Disease Drugs
  • Gene Therapy Drugs
  • Metabolic Disease Drugs
  • Others
Companies covered
  • Skyepharma
  • Asymchem
  • Recipharm
  • Bend Bioscience
  • Pierre Fabre
  • Axplora
  • Quotient Sciences
  • Lonza
  • Ardena
  • Hovione
  • Resilience
  • AGC Biologics
  • Patheon Pharma Services
  • Samsung Biologics
  • Catalent

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Innovative Drug CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Innovative Drug CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Innovative Drug CDMO Market Dynamics
  1. 2.1 Innovative Drug CDMO Industry Trends
  2. 2.2 Innovative Drug CDMO Industry Drivers
  3. 2.3 Innovative Drug CDMO Industry Opportunities and Challenges
  4. 2.4 Innovative Drug CDMO Industry Restraints
3 Innovative Drug CDMO Market by Company
  1. 3.1 Global Innovative Drug CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Innovative Drug CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Innovative Drug CDMO Company Ranking (2024-2026)
  4. 3.4 Global Innovative Drug CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Innovative Drug CDMO Company Product Type and Application
  6. 3.6 Global Innovative Drug CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Innovative Drug CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Innovative Drug CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Innovative Drug CDMO Market by Type
  1. 4.1 Innovative Drug CDMO Type Introduction
  2. 4.1.1 Small Molecule CDMO
  3. 4.1.2 Macromolecule CDMO
  4. 4.1.3 Cell Gene Therapy (CGT) CDMO
  5. 4.2 Global Innovative Drug CDMO Sales Value by Type
  6. 4.2.1 Global Innovative Drug CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Innovative Drug CDMO Sales Value by Type (2021-2032)
  8. 4.2.3 Global Innovative Drug CDMO Sales Value Share by Type (2021-2032)
5 Innovative Drug CDMO Market by Application
  1. 5.1 Innovative Drug CDMO Application Introduction
  2. 5.1.1 Oncology and Cancer Drugs
  3. 5.1.2 Autoimmune Disease Drugs
  4. 5.1.3 Rare Disease Drugs
  5. 5.1.4 Gene Therapy Drugs
  6. 5.1.5 Metabolic Disease Drugs
  7. 5.1.6 Others
  8. 5.2 Global Innovative Drug CDMO Sales Value by Application
  9. 5.2.1 Global Innovative Drug CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Innovative Drug CDMO Sales Value by Application (2021-2032)
  11. 5.2.3 Global Innovative Drug CDMO Sales Value Share by Application (2021-2032)
6 Innovative Drug CDMO Regional Value Analysis
  1. 6.1 Global Innovative Drug CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Innovative Drug CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Innovative Drug CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Innovative Drug CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Innovative Drug CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Innovative Drug CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Innovative Drug CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Innovative Drug CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Innovative Drug CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Innovative Drug CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Innovative Drug CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Innovative Drug CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Innovative Drug CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Innovative Drug CDMO Sales Value Share by Country, 2025 VS 2032
7 Innovative Drug CDMO Country-level Value Analysis
  1. 7.1 Global Innovative Drug CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Innovative Drug CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Innovative Drug CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Innovative Drug CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Innovative Drug CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Innovative Drug CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Innovative Drug CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Skyepharma
  2. 8.1.1 Skyepharma Company Information
  3. 8.1.2 Skyepharma Business Overview
  4. 8.1.3 Skyepharma Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Skyepharma Innovative Drug CDMO Product Portfolio
  6. 8.1.5 Skyepharma Recent Developments
  7. 8.2 Asymchem
  8. 8.2.1 Asymchem Company Information
  9. 8.2.2 Asymchem Business Overview
  10. 8.2.3 Asymchem Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Asymchem Innovative Drug CDMO Product Portfolio
  12. 8.2.5 Asymchem Recent Developments
  13. 8.3 Recipharm
  14. 8.3.1 Recipharm Company Information
  15. 8.3.2 Recipharm Business Overview
  16. 8.3.3 Recipharm Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Recipharm Innovative Drug CDMO Product Portfolio
  18. 8.3.5 Recipharm Recent Developments
  19. 8.4 Bend Bioscience
  20. 8.4.1 Bend Bioscience Company Information
  21. 8.4.2 Bend Bioscience Business Overview
  22. 8.4.3 Bend Bioscience Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bend Bioscience Innovative Drug CDMO Product Portfolio
  24. 8.4.5 Bend Bioscience Recent Developments
  25. 8.5 Pierre Fabre
  26. 8.5.1 Pierre Fabre Company Information
  27. 8.5.2 Pierre Fabre Business Overview
  28. 8.5.3 Pierre Fabre Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pierre Fabre Innovative Drug CDMO Product Portfolio
  30. 8.5.5 Pierre Fabre Recent Developments
  31. 8.6 Axplora
  32. 8.6.1 Axplora Company Information
  33. 8.6.2 Axplora Business Overview
  34. 8.6.3 Axplora Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Axplora Innovative Drug CDMO Product Portfolio
  36. 8.6.5 Axplora Recent Developments
  37. 8.7 Quotient Sciences
  38. 8.7.1 Quotient Sciences Company Information
  39. 8.7.2 Quotient Sciences Business Overview
  40. 8.7.3 Quotient Sciences Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Quotient Sciences Innovative Drug CDMO Product Portfolio
  42. 8.7.5 Quotient Sciences Recent Developments
  43. 8.8 Lonza
  44. 8.8.1 Lonza Company Information
  45. 8.8.2 Lonza Business Overview
  46. 8.8.3 Lonza Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lonza Innovative Drug CDMO Product Portfolio
  48. 8.8.5 Lonza Recent Developments
  49. 8.9 Ardena
  50. 8.9.1 Ardena Company Information
  51. 8.9.2 Ardena Business Overview
  52. 8.9.3 Ardena Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ardena Innovative Drug CDMO Product Portfolio
  54. 8.9.5 Ardena Recent Developments
  55. 8.10 Hovione
  56. 8.10.1 Hovione Company Information
  57. 8.10.2 Hovione Business Overview
  58. 8.10.3 Hovione Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hovione Innovative Drug CDMO Product Portfolio
  60. 8.10.5 Hovione Recent Developments
  61. 8.11 Resilience
  62. 8.11.1 Resilience Company Information
  63. 8.11.2 Resilience Business Overview
  64. 8.11.3 Resilience Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Resilience Innovative Drug CDMO Product Portfolio
  66. 8.11.5 Resilience Recent Developments
  67. 8.12 AGC Biologics
  68. 8.12.1 AGC Biologics Company Information
  69. 8.12.2 AGC Biologics Business Overview
  70. 8.12.3 AGC Biologics Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AGC Biologics Innovative Drug CDMO Product Portfolio
  72. 8.12.5 AGC Biologics Recent Developments
  73. 8.13 Patheon Pharma Services
  74. 8.13.1 Patheon Pharma Services Company Information
  75. 8.13.2 Patheon Pharma Services Business Overview
  76. 8.13.3 Patheon Pharma Services Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Patheon Pharma Services Innovative Drug CDMO Product Portfolio
  78. 8.13.5 Patheon Pharma Services Recent Developments
  79. 8.14 Samsung Biologics
  80. 8.14.1 Samsung Biologics Company Information
  81. 8.14.2 Samsung Biologics Business Overview
  82. 8.14.3 Samsung Biologics Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Samsung Biologics Innovative Drug CDMO Product Portfolio
  84. 8.14.5 Samsung Biologics Recent Developments
  85. 8.15 Catalent
  86. 8.15.1 Catalent Company Information
  87. 8.15.2 Catalent Business Overview
  88. 8.15.3 Catalent Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Catalent Innovative Drug CDMO Product Portfolio
  90. 8.15.5 Catalent Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst